Evidence map›Paper›PMID 37577651›Full record

ArticlebioRxiv : the preprint server for biology2024

Conserved regulatory motifs in the juxtamembrane domain and kinase N-lobe revealed through deep mutational scanning of the MET receptor tyrosine kinase domain.

Gabriella O Estevam, Edmond M Linossi, Christian B Macdonald, Carla A Espinoza, Jennifer M Michaud, Willow Coyote-Maestas, Eric A Collisson, Natalia Jura, James S Fraser

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 7 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Gabriella O EstevamDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco,United States.ORCID 0000-0002-9142-7805
Edmond M LinossiCardiovascular Research Institute, University of California San Francisco, San Francisco, United States.ORCID 0000-0002-8039-573X
Christian B MacdonaldDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco,United States.ORCID 0000-0002-0201-8832
Carla A EspinozaTetrad Graduate Program, University of California San Francisco, San Francisco, United States.ORCID 0009-0000-8702-0319
Jennifer M MichaudDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco,United States.ORCID 0000-0002-0872-0825
Willow Coyote-MaestasDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco,United States.ORCID 0000-0001-9614-5340
Eric A CollissonHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, United States.ORCID 0000-0001-8037-9388
Natalia JuraCardiovascular Research Institute, University of California San Francisco, San Francisco, United States.ORCID 0000-0001-5129-641X
James S FraserDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco,United States.ORCID 0000-0002-5080-2859
University of California, San Francisco · US

Funding

Optimizing Treatment Approaches to Lung Cancers Harboring MET Exon 14 mutationsR01CA239604 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COLLISSON, ERIC · 2019 to 2023
$2.0M
Illumina NovaSeq 6000 Sequencing SystemS10OD028511 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHOW, ERIC D · 2020 to 2020
$583k
Connecting structure and fitness landscapes to overcome antibiotic resistanceF32GM152977 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MACDONALD, CHRISTIAN BERNARD · 2023 to 2024
$146k
NCI NIH HHS R01 CA239604NIGMS NIH HHS F32 GM152977NIH HHS S10 OD028511
6 · The paper itself

Abstract

MET is a receptor tyrosine kinase (RTK) responsible for initiating signaling pathways involved in development and wound repair. MET activation relies on ligand binding to the extracellular receptor, which prompts dimerization, intracellular phosphorylation, and recruitment of associated signaling proteins. Mutations, which are predominantly observed clinically in the intracellular juxtamembrane and kinase domains, can disrupt typical MET regulatory mechanisms. Understanding how juxtamembrane variants, such as exon 14 skipping (METΔEx14), and rare kinase domain mutations can increase signaling, often leading to cancer, remains a challenge. Here, we perform a parallel deep mutational scan (DMS) of the MET intracellular kinase domain in two fusion protein backgrounds: wild type and METΔEx14. Our comparative approach has revealed a critical hydrophobic interaction between a juxtamembrane segment and the kinase αC-helix, pointing to potential differences in regulatory mechanisms between MET and other RTKs. Additionally, we have uncovered a β5 motif that acts as a structural pivot for the kinase domain in MET and other TAM family of kinases. We also describe a number of previously unknown activating mutations, aiding the effort to annotate driver, passenger, and drug resistance mutations in the MET kinase domain.

Identifiers

PMID37577651
PMCPMC10418267
OpenAlexW4385582521

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.